Besides its influenza pipeline, mRNA technology is helping this pharmaceutical company create a number of new vaccines for cancer, rare diseases, and infectious diseases.
Laboratory: ©Imaging L - stock.adobe.com
It’s a great day for mRNA technology, particularly in the field of infectious diseases. Today, Moderna announced it had met its primary endpoints in a phase 3 trial for the company’s influenza vaccine, mRNA-1010. The vaccine had generated a powerful response against all 4 influenza virus strains compared to traditional influenza shots in late-stage trials.
Moderna has recently shows positive clinical results with a number of vaccines in its pipeline, including the completion of a biologics license application for RSV (mRNA-1345); completion of enrollment in its adult phase 3 trial of mRNA-1647, a vaccine for cytomegalovirus (CMV); and a phase 3 trial of mRNA-1283, the next COVID-19 vaccine.
The company is taking advantage of its vast research and development in mRNA technology to add to its robust pipeline that includes clinical benefits for cancer, 3 different rare diseases, and a number of infectious disease vaccines. Six of the company’s programs are in late-stage development, and Moderna plans on doubling its number of programs in phase 3 by 2025, launching up to 15 products in 5 years across cancer, rare disease, and infectious diseases.
On September 11, 2023, the FDA approved a supplemental biologics license application for the COVID-19 vaccine Moderna, now called Spikevax, for persons aged 12 years and older, with emergency use authorization in infants and children aged 6 months to 11 years.
For seasonal influenza, mRNA-1010 vaccine has demonstrated safety and tolerability profiles across all clinical trials, including 3 phase 3 trials, and independent data and safety monitoring boards have raised no concerns.
Moderna continues to work on a number of other influenza vaccine candidates that include additional hemagglutinin (HA) antigens for broader coverage of influenza A strains, as well as a candidate that incorporates HA and neuraminidase antigens to target proteins found in the influenza virus lifecycle, to decrease the potential of viral antigenic escape (mRNA-1020 and mRNA-1030).
Additionally, the company is working on a number of combination vaccines for influenza/COVID-19, and influenza/RSV.
Other viruses that Moderna is working on to develop vaccines for include the Epstein Barr virus; the herpes simplex virus; varicella zoster virus; the norovirus; and HIV.
Reference
Moderna expans the field of mRNA mkedicine with positive clinical results across cancer, rare disease, and infectious disease. News release; Moderna. September 13, 2023. Accessed September 13, 2023. https://investors.modernatx.com/news/news-details/2023/Moderna-Expands-the-Field-of-mRNA-Medicine-with-Positive-Clinical-Results-Across-Cancer-Rare-Disease-and-Infectious-Disease/default.aspx#:~:text=Expanding%20the%20Field%20of%20mRNA%20Medicine&text=The%20Company%20has%20advanced%20a,1345%2C%20mRNA%2D1010).
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.